Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Empagliflozin in NODAT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Single kidney transplantation~* Normal glucose tolerance or Pre-Diabetes mellitus before transplantation~* According to Oral glucose tolerance test results to make the diagnosis of NODAT~* Standard triple immunosuppression therapy~* HbA1c≤10%~* Steady hormone usage~* BMI 18.5-30kg/m2~* Patient informed consent~Exclusion Criteria:~* Diabetes patients before transplantation~* Pregnancy pregnancy~* Type 1 diabetes after kidney transplantation~* Severe liver function impairment (AST/ALT 3 times standard value)~* Severely impaired renal function (eGFR\<45)~* Having uncontrolled diseases~* History of cancer in the past 5 years (except basal cell carcinoma) and/or cancer treatment~* Participating in another trial involving the study drug with in 30 days~* Premenopausal women (1 year before the last menstrual period ≤ informed consent)~* Alcohol or drug abuse within 3 months of informed consent, affecting compliance Need other drugs to control NODAT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: ACTIVE_COMPARATOR): Jardiance 10mg/25mg Film-coated tablets， once daily
- Linagliptin (Type: ACTIVE_COMPARATOR): Trajenta 5mg Film-coated tablets， once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).